Silence Therapeutics (SLN) Income from Continuing Operations (2024 - 2026)
Silence Therapeutics (SLN) reported Income from Continuing Operations of 14957000.0 for Q1 2026, up 47.57% on a YoY basis from 10135221.01 in Q1 2025, and down 27.08% sequentially from 11770000.0 in Q4 2025.
Silence Therapeutics (SLN) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Silence Therapeutics (SLN) has 3 years of Income from Continuing Operations data on file, last reported at 14957000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 47.57% year-over-year to 14957000.0; the trailing twelve-month figure through Mar 2026 stood at 75039000.0 (down 25.98% YoY), and the FY2025 full-year result was 88612000.0, down 165.72% from the prior year.
- Income from Continuing Operations fell to 14957000.0 in Q1 2026, from 11770000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 24263000.0 in Q4 2024 to a low of 35544000.0 in Q3 2024.
- A 3-year average of 15213000.0 and a median of 19755000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 1134.0% in 2025 and surged 47.57% in 2026, its largest moves.
- Tracing SLN's Income from Continuing Operations over 3 years: stood at 24263000.0 in 2024, then tumbled by 148.51% to 11770000.0 in 2025, then retreated by 27.08% to 14957000.0 in 2026.
- Business Quant data shows SLN's Income from Continuing Operations at 14957000.0 in Q1 2026, 11770000.0 in Q4 2025, and 20958000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Silence Therapeutics | 1.62 Bn | 1.49 Bn | 411,000.00 | -14.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.96 Mn |
| Dec 31, 2025 | -11.77 Mn |
| Sep 30, 2025 | -20.96 Mn |
| Jun 30, 2025 | -27.35 Mn |
| Mar 31, 2025 | -28.53 Mn |
| Dec 31, 2024 | 24.26 Mn |
| Sep 30, 2024 | -35.54 Mn |
| Jun 30, 2024 | -19.76 Mn |
| Mar 31, 2024 | -2.31 Mn |